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ABSTRACT—Pulmonary edema, a major manifestation of left ventricular heart failure, renal insufficiency, shock, diffuse 
alveolar damage and lung hypersensitivity states, is a significant medical problem worldwide and can be life-threatening. The 
proinflammatory cytokine tumor necrosis factor (TNF) has been shown to contribute to the pathogenesis and development 
of pulmonary edema. However, some recent studies have demonstrated surprisingly that TNF can also promote alveolar 
fluid reabsorption in vivo and in vitro. This protective effect of the cytokine is mediated by the lectin-like domain of the 
cytokine, which is spatially distinct from the TNF receptor binding sites. The TIP peptide, a synthetic mimic of the lectin-
like domain of TNF, can significantly increase alveolar fluid clearance and improve lung compliance in pulmonary edema 
models. In this review, we will discuss the dual role of TNF in pulmonary edema.
Abbreviations:—tumor necrosis factor (TNF); acute lung injury (ALI); acute respiratory distress syndrome (ARDS); positive 
end-expiratory  pressure  (PEEP);epithelial  sodium  channel  (ENaC);neural  precursor  cell-expressed  developmentally 
downregulated (gene 4) protein (Nedd4-2);serum and glucocorticoid dependent kinase (Sgk-1);insulin-like growth factor 1 
(IGF-1);Protein Kinase C (PKC);reactive oxygen species (ROS);myosin light chain (MLC);pneumolysin (PLY);listeriolysin 
(LLO);interleukin (IL);bronchoalveolar lavage fluids (BALF);Bacillus Calmette-Guerin (BCG);TNF receptor type 1 (TNF-
R1); TNF receptor type 2 (TNF-R2);
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PULMONARY EDEMA
Pulmonary edema, defined as an increase in lung water content, 
occurs  when  the  rate  of  fluid  movement  out  of  the  lung’s 
microvasculature exceeds the capacity of the lymphatics to clear 
the fluid from the lung’s interstitium 1. Despite much research 
pulmonary edema remains one of the more common causes for 
admission to the hospital and intensive care units 2.
1.1 Mechanisms of Pulmonary Edema Formation
The  alveolar–capillary  barrier  is  comprised  of  capillary 
endothelium and of alveolar epithelium. Pulmonary alveoli, the 
primary sites of gas exchange with the blood, are composed of 
a thin alveolar epithelium (0.1–0.2 μm) that covers 99% of the 
airspace surface area in the lung and contains thin, squamous 
type I cells and cuboidal type II cells 3. Type I cells cover 95% 
of the alveolar surface and are also the apposition between the 
alveolar  epithelium and  the vascular  endothelium. This area 
facilitates efficient gas exchange and forms a tight barrier to 
fluid and protein movement from the interstitial and vascular 
spaces, thereby maintaining relatively dry alveoli. Tight junctions 
connect adjacent epithelial cells near their apical surfaces and 
maintain apical and basolateral cell polarity. These junctions 
are  critical  elements  of  the  permeability  barrier  required  to 
maintain discrete compartments in the lung 4. The alveolar type 
II cell, known for surfactant secretion, is thought to contribute 
to  the  vectorial  transport  of  sodium  5.  Active  transport  of 
sodium provides a major driving force for fluid removal from 
the alveolar space. Amiloride-sensitive sodium channels on the 
apical surface, mainly the epithelial sodium channel ENaC, are 
involved in fluid transport, with the driving force represented 
by the Na+/K+-ATPase on the basolateral surface 3.
Besides  pulmonary  epithelia,  endothelial  barrier  function 
is also a key component for maintenance of the integrity of 
the vascular boundaries in the lung, particularly since the gas 
exchange surface area of the alveolar-capillary membrane is 
large 6. The endothelial cell lining of the pulmonary vasculature 
forms  a  semipermeable  barrier  between  the  blood  and  the 
interstitium of the lung. Disruption of this barrier can occur 
during inflammatory disease states, such as pneumonia, acute 
lung injury (ALI) and the acute respiratory distress syndrome The Dual Role of TNF in Pulmonary Edema
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(ARDS). This barrier dysfunction can result in the movement of 
fluid and macromolecules into the interstitium and pulmonary 
air spaces, processes which significantly contribute to the high 
morbidity and mortality of patients afflicted with acute lung 
injury 7.
Although many diseases cause pulmonary edema, they do 
so by means of one or a combination of the following three 
processes:
  i)    An increased capillary pressure in the lungs;
 ii)    An  increased  permeability  or  disruption  of  the  alveolar 
epithelial-endothelial barrier (permeability edema);
iii)    A dysregulated expression or function of crucial ion channels 
in type II alveolar epithelial cells (type II AEC) implicated in 
lung liquid clearance, such as the apically expressed epithelial 
sodium  channel  ENaC  and  the  basolaterally  expressed   
Na+/K+-ATPase.
As  a  consequence,  a  reduction  of  lung  compliance  and  an 
impaired gas exchange may occur, leading to hypoxemia and 
respiratory  acidosis.  Patients  with  pulmonary  edema  show 
typical symptoms, including shortness of breath, lung-crackling 
sounds, pink-stained sputum, cough, anxiety, breathing difficulty, 
restlessness and wheezing.
1.2 Classification of Pulmonary Edema
Pulmonary  edema  is  differentiated  into  two  categories: 
cardiogenic and non-cardiogenic edema 8.
1.2.1 Cardiogenic pulmonary edema
Cardiogenic pulmonary edema is defined as pulmonary edema 
due to increased capillary hydrostatic pressure, secondary to 
elevated pulmonary venous pressure 9, it is also called hydrostatic 
edema or hemodynamic edema 10. In case of cardiogenic edema, 
a causal therapy of the underlying disease is often preceded by 
a symptomatic treatment of the impaired gas exchange, e.g. 
by means of non-invasive ventilation, paralleled by efficient 
medical interventions.
1.2.2 Non-cardiogenic pulmonary edema
Non-cardiogenic pulmonary edema occurs due to changes in 
permeability of the pulmonary capillary or alveolar epithelial 
membranes, as a result of either a direct or an indirect pathological 
process and is therefore also known as permeability pulmonary 
edema 10. It represents a spectrum of illnesses, ranging from the 
less severe form of ALI to ARDS. The mainstay of treatment 
is mechanical ventilation with maximization of ventilation and 
oxygenation through the judicious use of positive end-expiratory 
pressure (PEEP). Newer ventilation techniques, such as high-
frequency oscillatory ventilation and partial fluid ventilation, 
are promising but are still in the early stages of clinical testing. 
Mortality  rates  unfortunately  remain  high,  despite  increased 
therapy developments in the intensive care unit 8.
As  indicated  above,  in  the  clinics,  hydrostatic  edema  is 
mostly a consequence of heart failure, whereas non-cardiogenic 
pulmonary  edema  is  mostly  a  consequence  of  acute  lung 
inflammation. ARDS is a medical emergency, characterized by 
the sudden failure of the respiratory system. In 2007, the NHLBI 
estimated that approximately 190,000 Americans are affected 
by ARDS annually 11. Approximately 40% of ARDS cases are 
fatal, with a mortality rate of even 60% in patients aged 85 years 
and older 12. There is accumulating evidence that the capacity of 
the lung to clear edema liquid is essential for outcome in both 
cardiogenic  and  non-cardiogenic  pulmonary  edema.  Patients 
with ARDS have a dramatically reduced life expectancy when 
their fluid reabsorption capacity is impaired13.
Apart from strategies to optimize ventilation procedures, 
currently no standard therapy exists for permeability edema. 
Moreover, viral and bacterial infections can induce a change 
in  the  expression  or  function  of  epithelial  sodium  channel 
(ENaC). Therefore, the search for substances able to reduce 
the endothelial hyperpermeability and/or restore the sodium 
uptake in type II AEC is important.
1.3 Regulation of ENaC Expression and Activity
The surface expression of ENaC is mainly regulated via the 
neural precursor cell-expressed developmentally downregulated 
(gene  4)  protein  (Nedd4-2),  which  leads  to  ubiquitinylation 
and subsequent degradation of the sodium channel. Specific 
kinases,  such  as  the  cell  volume  stress-activated  serum  and 
glucocorticoid  dependent  kinase  (Sgk-1)  and  Akt1  (protein 
kinase B), both part of the insulin and insulin-like growth factor 
1 (IGF-1) signaling pathway, were recently proposed to control 
the surface expression of ENaC, by means of phosphorylating 
Nedd4-2 and subsequently reducing its binding to ENaC14,15.
Alternatively,  Sgk1  has  been  shown  to  phosphorylate 
iNOS in type II alveolar epithelial cells, as such reducing NO 
production,  which  inhibits  Na+  transport16.  PI3-kinase  can 
also counteract Protein Kinase C (PKC) activity. PKC is an 
important  negative  regulator  of  ENaC  expression.  Recently 
PKC alpha (PKC-α) and zeta isozymes were found to be crucial 
in ENaC downregulation caused by proteins of SARS-CoV 17 
and of Influenza A virus18. Recently, also oxidative stress, which 
often occurs in the lung under conditions such as infection and 
inflammation, has been demonstrated to interfere with ENaC 
expression. Indeed, in lung epithelial cell lines, such as H441 
and Calu3 cells, H2O2-mediated oxidative stress was shown to 
reduce the expression of the alpha subunit of ENaC19. In this 
regard, it is interesting to note that the main etiological agent 
of community acquired pneumonia, i.e. Streptococcus pneumoniae, 
lacks  catalase  and  therefore  secretes  H2O2  as  a  virulence 
factor20.
1.4 Regulation of Endothelial Permeability.
Within endothelial cells, three primary signaling pathways are 
initiated by the binding of vasoactive factors and leukocyte 
adhesion:  Rho  GTPases,  reactive  oxygen  species  (ROS), 
and  tyrosine  phosphorylation  of  junctional  proteins.  These 
pathways converge to regulate junctional permeability, either by 
affecting the stability of junctional proteins or by modulating 
their interactions. The regulation of junctional permeability is 
mediated by dynamic interactions between the proteins of the 
adherens junctions, which represent 80% of the tight junctions 
in endothelial cells and the actin cytoskeleton21. Actin/myosin-
driven contraction generates a contractile force that pulls VE-
cadherin inward, thus forcing it to dissociate from its adjacent 
partner,  as  such  producing  interendothelial  gaps.  Another 
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and  interendothelial  gap  formation  involves  microtubule 
disassembly.
A rise in cytosolic Ca2+ has been proposed to be the initial 
pivotal signal preceding endothelial cell contraction, since it 
can activate key signaling pathways, that mediate cytoskeletal 
reorganization (through myosin light chain (MLC)-dependent 
contraction) and disassembly of VE-cadherin at the adherens 
junctions.  Rho  (Ras  homologous)  GTP-binding  proteins, 
which  comprise  multiple  members  of  the  Rho,  Rac  and 
Cdc42 subfamilies, are involved in the regulation of a variety 
of cellular processes 21. Both RhoA and Rac1 play important 
roles  in  the  regulation  of  cytoskeletal  remodeling  and  EC 
barrier  regulation22–27.  RhoA  and  Rho-associated  kinase  may 
directly  catalyze  MLC  phosphorylation  or  act  indirectly  via 
inactivation of MLC phosphatase28,29 to induce cell contraction 
and endothelial barrier disruption. In turn, endothelial barrier 
enhancement  is  associated  with  Rac  1-mediated  formation 
of F-actin, increased association of focal adhesion proteins, 
and enlargement of intercellular adherens junctions 7. Thus, a 
precise balance between RhoA- and Rac1-mediated signaling is 
essential for endothelial barrier regulation.
The Ca2+-dependent PKC isoform, PKC-α, was suggested 
to play a critical role in initiating endothelial cell contraction 
and disassembly of VE-cadherin junctions21,30. The NADPH 
oxidases,  NOX2  and  NOX4,  are  major  sources  of  ROS  in 
endothelial cells and are implicated in redox-sensitive signaling 
pathways that  influence endothelial  cytoskeletal organization 
and  permeability31.  Apart  from  inducing  RhoA  activation32, 
PKC-α activation was also recently shown to upregulate NOX 
4 mRNA expression in human endothelial cells33.
1.5 Role of Bacterial Exotoxins in ALI
Death  in  severe  bacterial  pneumonia  can  occur  days  after 
initiation  of  antibiotic  therapy,  when  tissues  are  sterile  and 
the pneumonia is clearing and correlates with the presence of 
bacterial toxins34. There is growing evidence that aspects of 
the immune response greatly contribute to the high mortality 
rate: while immunosuppressed patients die as a consequence 
of  a  poor  host  response,  immunocompetent  hosts  face 
overwhelming inflammatory reactions that contribute to tissue 
injury, shock, and death. In view of its crucial role in bacterial 
virulence and its profound effects on the immune system of 
the host, the pore-forming toxin pneumolysin (PLY, from S. 
pneumoniae) and its homologous toxin listeriolysin (LLO, from 
Listeria monocytogenes) can be considered as model toxin for G+ 
infection-associated acute lung injury and permeability edema.
These toxins bind to cholesterol, followed by oligomerization 
and membrane pore formation, resulting in a rapid increase 
in intracellular Ca2+ and diacylglycerol levels35 and in severe 
pulmonary hyperpermeability36. The interaction of Streptococcus 
pneumoniae with endothelial cells represents a crucial step in its 
pathogenesis. Intravascular PLY was shown to cause a significant 
dose-dependent increase in pulmonary vascular resistance and 
in lung microvascular permeability. By immunohistochemistry, 
PLY could be detected mainly in endothelial cells of pulmonary 
arterial  vessels,  which  concomitantly  displayed  strong 
vasoconstriction and the toxin moreover increased permeability 
of HUVEC monolayers36. We could recently show that sublytic 
concentrations  of  LLO  induces  cholesterol-dependent  actin 
remodeling by means of interfering with the activity of the 
small  GTP  binding  proteins  RhoA  and  Rac1  in  pulmonary 
human microvascular endothelial cells 37.
CYTOKINES IN PULMONARY EDEMA
2.1 Role of Cytokines in Pulmonary Edema
It has been known that inflammation plays an important role 
in  the  pathogenesis  of  pulmonary  edema.  Once  a  systemic 
inflammatory response is triggered, circulating monocytes and 
alveolar  macrophages  and  neutrophils  can  secrete  cytokines 
and chemokines, including TNF, interleukin-1β (IL-1β), IL-6, 
IL-8, IL-12, interferon-γ and IL-8  38-40. Substantial evidence 
suggests that cytokines are important mediators of the lung 
injury that follows infection or exposure to microbial products 
40. TNF also plays an important role in the activation of host 
defense  by  promoting  the  production  of  a  wide  spectrum 
of other cytokines and chemokines, such as IL-1, IL-6, IL-8, 
and  granulocyte/macrophage  colony  stimulating  factor  in 
inflammatory processes41,42. These pro-inflammatory cytokines 
activate  leukocytes  and  endothelial  cells  so  that  these  cells 
increase  the  expression  of  surface  adhesion  molecules. 
Neutrophils,  other  leukocytes,  and  platelets  adhere  via 
cognate  receptors  to  the  pulmonary  endothelium.  Activated 
neutrophils  release  proteases,  leukotrienes,  reactive  oxygen 
intermediates, and other inflammatory molecules that amplify 
the  inflammatory  response.  ROS  and  proteases  can  directly 
damage alveolar–capillary membrane integrity 43. ROS have also 
been implicated in ischemia-reperfusion damage following lung 
transplantation44.
Up to date, many studies have shown that TNF can contribute 
to  the  pathogenesis  and  development  of  pulmonary  edema 
45-53. Upon checking the cytotoxic effects on the pulmonary 
endothelium  of  bronchoalveolar  lavage  fluids  (BALF)  from 
different  groups  of  patients,  we  found  significantly  higher 
TNF levels in the BALF from patients with early-stage ARDS, 
as compared to control, at risk or late-stage ARDS patients, 
indicating the implication of this cytokine in barrier dysfunction 
during the acute phases of the syndrome 54.
By  contrast,  new  evidence  has  emerged  suggesting  that 
TNF  can  stimulate  lung  liquid  clearance  55-57  and  that  the 
neutralization of this cytokine with neutralizing antibodies can 
increase the accumulation of edema fluid 58. Therefore, the role 
of TNF in the regulation of alveolar liquid clearance and active 
sodium transport is still controversial, which is why others and 
our group have tried to unravel its mechanisms of action in 
edema formation and reabsorption 59.
2.2 Tumor Necrosis Factor (TNF)
TNF was first identified in 1975 as a cytokine with anti-tumor 
effects in vitro and in vivo 60. Extensive research since then has 
shown that there are at least 18 distinct members of the TNF 
superfamily exhibiting 15–25% amino acid sequence homology 
with each other 61. Among all the members, TNF is the most 
widely studied pleiotropic cytokine 62. Although TNF was first 
identified for its ability to induce rapid hemorrhagic necrosis of 
cancers 63, over the years it has become increasingly clear that 
the cytokine is major component of the inflammatory response 
and thus its overproduction can play important roles in many The Dual Role of TNF in Pulmonary Edema
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diseases of the cardiovascular  64, respiratory  62,65, endocrinal, 
metabolic 66,67, nervous 68 and skeletal systems 69.
2.2.1 The Discovery of  TNF
TNF is a potent proinflammatory cytokine produced by many 
cell  types,  including  monocytes,  macrophages,  lymphocytes, 
endothelial cells and fibroblasts 70. TNF was found in the serum 
of Bacillus Calmette-Guerin (BCG)-infected mice, and got its 
name in 1975 by Dr. Old for its ability to mediate endotoxin-
induced hemorrhagic necrosis71. In the early 1980’s the groups 
of Fiers and Pennica independently cloned TNF cDNA and 
revealed that it has about 30% homology in its amino acid 
sequence with lymphotoxin (LT), a lymphokine with similar 
biological properties60,72. The similarity between TNF and LT 
both in sequence and function lead to the renaming of TNF as 
TNF-α and LT as TNF-β. In the meanwhile, this nomenclature 
has been changed to TNF and LT-β. Kriegler et al., identified and 
characterized a rapidly inducible cell surface cytotoxic integral 
transmembrane form of TNF and named it membrane TNF 
73. In 1997, Black et al., found that this membrane-integrated 
TNF can be specifically released via proteolytic cleavage by the 
metalloprotease TNF-alpha-converting enzyme and inactivation 
of its coding gene in mouse cells caused a marked decrease in 
soluble TNF production 74.
2.2.2 The TNF Receptors
Two specific receptors interact with TNF on the cell surface: 
TNF-R1 (TNF receptor type 1; CD120a; p55/60) and TNF-R2 
(TNF receptor type 2; CD120b; p75/80)75. TNF-R1 is expressed 
in most tissues, and can be fully activated by both the membrane-
bound and soluble trimeric forms of TNF, whereas TNF-R2 
is found only in cells of the immune system, and respond to 
the membrane-bound form of the TNF homotrimer75. While 
sharing  structural  similarities  in  their  extracellular  domains, 
the two TNFRs differ in their intracellular domain, their signal 
transduction, and consequently their function 76. The receptor-
ligand  interaction  causes  intracellular  signaling  without 
internalization of the complex, which leads to phosphorylation 
of NF-kB to activate the p50-p65 subunit, which interacts with 
the DNA chromatin structure to increase transcription of pro-
inflammatory genes, such as IL-8, IL-6 and TNF-α 77.
2.2.3 The Lectin-like Domain of  TNF
Although it is generally assumed that cytokines solely exert their 
activities upon activating their respective receptors, this does 
not seem to be completely true in the case of TNF. Indeed, in 
contrast to Lymphotoxin-alpha, which has a highly homologous 
3-D structure as TNF and which is able to bind to both TNF 
receptors, TNF was shown to exert a lytic activity in purified 
long slender bloodstream forms of African trypanosomes by 
means of a lectin-like interaction with oligosaccharide residues 
on the surface of the parasites 78. Through investigation, it was 
found that this lectin-like activity can be attributed to a special 
domain, named the lectin-like domain of TNF  79,80, which is 
spatially distinct from its receptor binding sites81. This is further 
confirmed by the finding that N, N’-diacetylchitobiose, a specific 
binding oligosaccharide of this lectin-like domain, can block 
this trypanolytic effect whereas it leaves the cytotoxic activity 
of TNF in cancer cells lines unaffected 81.
Moreover, a circular seventeen amino acid peptide, named 
the TIP peptide, (a derivative of the tip region of TNF), 
mimics the functional structure of this lectin-like domain 
and  has  similar  lytic  effect  on  African  trypanosomes 
81.  In  recent  years,  more  evidence  has  been  collected 
demonstrating that this TNF domain is distinct from the 
two classical receptors, not only regarding its location in 
the TNF molecule, but also in its functions in different 
physiopathological processes.
DELETERIOUS EFFECTS OF TNF  
IN PULMONARY EDEMA
3.1 Effects of TNF on Sodium Uptake Capacity in 
Type II AEC
Type II alveolar epithelial cells and small airway epithelial cells 
represent the primary sites for reabsorption of Na+ in the lung. 
Na+ ions in the alveolar lining fluid were shown to passively 
diffuse into fetal distal lung epithelial and alveolar epithelial 
type II cells through nonselective cationic channels and Na+ 
selective, amiloride-sensitive channels, the most important of 
which is the epithelial sodium channel ENaC, located in the 
apical membrane, consisting of at least 4 subunits, i.e. alpha, 
beta, gamma and delta 82, with the former one being crucial 
for its activity 83. The favorable electrochemical driving force 
for Na+ influx is maintained by the basolaterally expressed, 
ouabain-sensitive Na+/ K+-ATPase that transports Na+ into 
the interstitial space 84. Epithelial Na+ channels represent the 
rate-limiting step in Na+ absorption 85,86. Active Na+ transport 
across the alveolar epithelium in vivo was proposed to help 
the  reabsorption  of  fetal  fluid  after  birth  and  to  keep  the 
adult alveolar spaces free of fluid, especially when alveolar 
permeability to plasma proteins has been increased 87. Recent 
data studying mice with reduced ENaC activity also clearly 
illustrate  the  impaired  lung  fluid  clearance  in  these  adult 
mice88.
During inflammatory processes in the lungs, proinflammatory 
substances such as TNF are produced locally. Indeed, it has 
been demonstrated that there is an elevation of the TNF level 
in the BALF from patients with ALI/ARDS 48. Dagenais et al 
found that TNF decreased the expression of the alpha-, beta-, 
and gamma-subunits ENaC mRNA to 36, 43, and 16% of the 
controls after 24 hour treatment and reduced to 50% the amount 
of alpha-ENaC protein in these cells. There was no impact, 
however, on Na+/K+-ATPase mRNA expression. Moreover, 
in the same study, TNF decreased amiloride-sensitive sodium 
uptake in a dose-dependent manner 89. In further investigations, 
the potential role of TNF on ENaC promoter activity was 
tested in A549 alveolar epithelial cells; the result showed that 
TNF  decreased  luciferase  expression  by  25%  in  these  cells, 
indicating that the strong diminution of ENaC mRNA must be 
related to posttranscriptional events 90. A recent study suggested 
that at least in the kidneys, the inhibitory effect of TNF on 
ENaC expression occurs through a TNF-R1-induced ceramide-
dependent mechanism 91. In 2009, Yamagata et al. reported that 
direct exposure of rat alveolar type II cells to TNF inhibited 
the mRNA expression of alpha- and gamma-ENaC to 64.0 and 
78.0%, but not that of the beta-ENaC; and reduced amiloride-
sensitive current 59.J Cardiovasc. Dis. Res.  Vol 1 / No 1   |  Available Online : www.jcdronline.org  33
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3.2 Effects of TNF on Permeability of Epithelial-
endothelial Barrier
One  prominent  feature  of  acute  lung  injury  syndromes  is 
the  disruption  of  the  vascular  barrier,  which  can  result  in 
permeability  pulmonary  edema  formation  and  subsequent 
respiratory  dysfunction  92.  The  critical  importance  of  the 
pulmonary vascular barrier function is shown by the balance 
between competing endothelial cell contractile forces, which 
generate  centripetal  tension,  and  adhesive  cell-cell  and  cell-
matrix  tethering  forces,  which  regulate  cell  shape.  Both 
competing forces in this model are intimately linked through 
the  endothelial  cytoskeleton,  a  complex  network  of  actin 
microfilaments,  microtubules,  and  intermediate  filaments, 
which combine to regulate shape change and transduce signals 
within and between endothelial cells 7.
TNF  can  trigger  endothelial  cell  activation  and  barrier 
dysfunction, which are both implicated in the pathogenesis of 
pulmonary edema  93. In 1989, Goldblum et al observed that 
human  recombinant  TNF  could  provoke  acute  pulmonary 
vascular  endothelial  injury  and  increase  pulmonary  vascular 
permeability  in  vivo  as  well  as  in  vitro  94.  In  another  study, 
TNF is shown to increase the permeability of endothelial cell 
monolayers  to  macromolecules  and  lower  molecular  weight 
solutes by a mechanism involving a pertussis toxin-sensitive 
regulatory G protein 95. In 1993, Wheatley’s study also showed 
that TNF could increase the permeability of lung endothelial cell 
monolayers and that fibronectin could blunt this effect 96, while 
Partridge revealed that the TNF-induced increase in endothelial 
permeability involves the loss of fibronectin and remodeling of 
the extracellular matrix 97. It has also been shown that TNF can 
increase capillary permeability causing transcapillary filtration 
in vivo 98.
More recent studies have demonstrated that TNF can cause 
microtubule rearrangement in monolayers of human pulmonary 
artery endothelial cells93.
3.3 Other Mechanisms
Besides  the  direct  deleterious  effects  on  Na+  channel  and 
barrier dysfunction, it was also reported that TNF can induce 
pulmonary edema by means of augmenting reactive oxygen 
species 53, which has been shown to be able to disrupt pulmonary 
endothelial barrier99 and to decrease Na+ channel activity100.
PROTECTIVE EFFECTS OF TNF 
IN PULMONARY EDEMA
4.1 Positive Effects of TNF on ENaC Function.
Intriguingly, while many studies have already shown that TNF 
contributes  to  the  formation  of  pulmonary  edema,  other 
researchers  have  found  that  this  pro-inflammatory  cytokine 
can actually increase the clearance of alveolar liquid, mainly in 
infection models.
In 1997, Rezaiguia et al revealed that the instillation of TNF 
in rats infected with Pseudomonas aeruginosa increased alveolar 
liquid clearance by 43% over 1 h, as compared to control rats. 
Moreover, when an anti-TNF neutralizing antibody was instilled 
into the lungs 5 min before the bacteria, alveolar liquid clearance 
was significantly decreased 56. The results of Borjesson’s study 
suggested that intestinal ischemia-reperfusion in a rat model 
leads to stimulation of alveolar liquid clearance and that this 
stimulation is mediated, at least in part, by a TNF-dependent 
mechanism, independent from catecholamine release, because 
propranolol  had no effect and there was no stimulation of 
cAMP 55.
In 1997, a triple-mutant murine TNF was generated upon 
replacement of the crucial residues Thr104, Glu106, and Glu109 
with alanines in the lectin-like domain of the TNF trimer. As 
such, TNF lost its lectin-like affinity, essentially retained its TNF 
receptor 1-mediated activities, but displayed a 50-fold- reduced 
TNF receptor 2-mediated bioactivity in vitro 101. We subsequently 
demonstrated  that  TNF  can  increase  sodium  uptake  by  an 
amiloride-sensitive,  cAMP-independent  mechanism  in  A549 
cells,  by  means  of  its  lectin-like  domain  102.  As  shown  in 
Hribar et al., 1999, TNF causes a pH-dependent increase in 
sodium current in primary lung microvascular endothelial cells 
and peritoneal macrophages; in a TNF receptor-independent, 
amiloride-dependent  manner,  since  it  also  occurs  in  cells 
isolated from mice deficient in both TNF receptor types. In 
this study, the TIP peptide also increased the sodium currents 
in these cells 103.
4.2 Positive Effects of the Lectin-like Domain of 
TNF on Permeability of the Epithelial-endothelial 
Barrier
In isolated endo/exotoxin-treated perfused rabbit lungs, Vadasz 
et al., recently demonstrated that the TNF-derived TIP peptide 
significantly  lowered  vascular  permeability,  as  assessed  by 
capillary  filtration  coefficient  and  fluorescein  isothiocyanate-
labeled albumin flux across the alveolocapillary barrier 104.
Infections  with  the  G+  bacterium  Listeria  monocytogenes 
can  cause  severe  lung  complications,  which  can  result  in 
permeability  edema,  characterized  by  an  extensive  capillary 
endothelial  hyperpermeability,  which  requires  harsh 
therapeutic measures and often has a fatal outcome 34. LLO, 
the main virulence factor of Listeria monocytogenes, induces a 
dose-dependent hyperpermeability in monolayers of human 
lung  microvascular  endothelial  cells  in  vitro.  In  our  recent 
study, The TNF-derived TIP peptide, which mimics the lectin-
like domain of the cytokine, was shown to blunt LLO-induced 
hyperpermeability  in  vitro,  upon  inhibiting  LLO-induced 
PKC-α activation, ROS generation and MLC phosphorylation 
and upon restoring the RhoA/Rac 1 balance. These results 
indicate that the lectin-like domain of TNF has a potential 
therapeutic value in protecting from LLO-induced pulmonary 
endothelial hyperpermeability 37.
4.3 Protective Effects of the Lectin-like  
Domain of TNF on ROS Generation  
during Ischemia-Reperfusion Injury
In a recent study, we could demonstrate that the TIP peptide, 
which mimics the lectin-like domain of TNF, is able to blunt 
ROS production in pulmonary artery endothelial cells under 
hypoxia and reoxygenation, and reduces ROS content in the 
transplanted  rat  lungs  in  vivo,  whereas  the  inactive  mutant 
TIP  peptide  didn’t  have  this  effect.  Using  Ussing  chamber 
experiments of primary type II rat pneumocytes, we concluded 
that the primary site of action of the peptide is on the apical side The Dual Role of TNF in Pulmonary Edema
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of these cells, since only apical, but not basolateral stimulation 
of the monolayers with the TIP peptide resulted in increased 
amiloride-sensitive transepithelial currents 44.
Active  Na+  transport  across  the  alveolar  epithelium  is 
regulated  via  not  only  apically  expressed  Na+  and  chloride 
channels,  but  also  by  means  of  the  basolaterally  expressed 
Na+/K+-ATPase in normal and injured lungs 105. The study of 
Vadasz et al, 2008, found that the TIP peptide increased Na+/
K+-ATPase activity 1.6-fold by promoting its exocytosis to the 
alveolar epithelial cell surface and increased amiloride-sensitive 
sodium uptake, resulting in a 2.2-fold increase in active Na+ 
transport, and hence improved clearance of excess fluid from 
the alveolar space 104. Our Ussing chamber results would rather 
indicate an indirect role of the Na+/K+-ATPase in these effects, 
upon a previous stimulation of ENaC.
SUMMARY AND FUTURE PERSPECTIVES
Pulmonary edema is still one of the most common medical 
emergencies,  with  no  standard  therapy  available  for  the 
permeability-induced form of the pathology. As an important 
cytokine  being  involved  in  this  pathogenesis,  TNF  is  an 
example of a “moonlighting protein”, with differential activities 
mediated by its receptor-binding versus its lectin-like domains, 
which  opens  the  possibility  to  design  and  develop  more 
sophisticated therapeutic regimens to overcome the deleterious 
fluid accumulation in some major lung pathologies 47.
In our opinion, the studies mentioned above can generate 
important advances in our understanding of the complexity of 
the TNF effects in pulmonary edema. However, in the future, 
more  research  is  needed  in  order  to  reveal  the  underlying 
mechanisms  of  TNF’s  protective  versus  deleterious  effects. 
This research can potentially make the lectin-like domain of 
TNF an attractive therapeutic option in patients with pulmonary 
permeability edema.
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